{"filing":{"accession_number":"0001628280-26-052558","cik":"0001673743","ticker":"HNGE","company_name":"Hinge Health, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-29","primary_document":"hnge-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1673743/000162828026052558/hnge-20260729.htm"},"events":[{"id":24043,"run_id":21748,"accession_number":"0001628280-26-052558","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Hinge Health announced Q2 2026 financial results with revenue of $212.8 million (53% YoY growth), GAAP net income of $43.7 million, and free cash flow of $99.6 million, along with raised full-year 2026 revenue guidance to $858 million.","company_name":"Hinge Health, Inc.","ticker":"HNGE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24436,"accession_number":"0001628280-26-052558","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 2.02 disclosure announces Hinge Health's Q2 2026 financial results with revenue of $212.8 million (53% YoY growth), GAAP net income of $43.7 million, and free cash flow of $99.6 million. The press release (Exhibit 99.1) contains detailed financial statements, operating metrics, and forward guidance for Q3 and full-year 2026. This is a standard earnings release disclosure material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24437,"accession_number":"0001628280-26-052558","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references supplemental investor materials posted to the company's investor relations website. The attached Exhibit 99.1 is a comprehensive earnings release announcing Q2 2026 financial results (revenue of $213 million, 53% YoY growth, net income of $43.7 million) and raising full-year 2026 revenue guidance to $858 million. While the Item 7.01 itself is a routine Regulation FD notice, the substantive disclosure is the earnings release, which is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":24044,"run_id":21748,"accession_number":"0001628280-26-052558","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Hinge Health entered into a definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, expanding the company's offerings into gastrointestinal care.","company_name":"Hinge Health, Inc.","ticker":"HNGE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24438,"accession_number":"0001628280-26-052558","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure centers on Hinge Health's entry into a definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, expanding into gastrointestinal care. While the section also mentions a $300 million increase to the share repurchase program, the acquisition is the material event—it represents a strategic M\u0026A transaction that would affect investor assessment of the company's growth trajectory and capital allocation. The press release (EX-99.1) confirms this is the lead announcement: \"Signed a definitive agreement to acquire Cylinder Health, Inc., expanding into gastrointestinal care.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24436,"accession_number":"0001628280-26-052558","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 2.02 disclosure announces Hinge Health's Q2 2026 financial results with revenue of $212.8 million (53% YoY growth), GAAP net income of $43.7 million, and free cash flow of $99.6 million. The press release (Exhibit 99.1) contains detailed financial statements, operating metrics, and forward guidance for Q3 and full-year 2026. This is a standard earnings release disclosure material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"Hinge Health, Inc.","ticker":"HNGE","filing_date":"2026-08-04"},{"id":24437,"accession_number":"0001628280-26-052558","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references supplemental investor materials posted to the company's investor relations website. The attached Exhibit 99.1 is a comprehensive earnings release announcing Q2 2026 financial results (revenue of $213 million, 53% YoY growth, net income of $43.7 million) and raising full-year 2026 revenue guidance to $858 million. While the Item 7.01 itself is a routine Regulation FD notice, the substantive disclosure is the earnings release, which is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"Hinge Health, Inc.","ticker":"HNGE","filing_date":"2026-08-04"},{"id":24438,"accession_number":"0001628280-26-052558","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure centers on Hinge Health's entry into a definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, expanding into gastrointestinal care. While the section also mentions a $300 million increase to the share repurchase program, the acquisition is the material event—it represents a strategic M\u0026A transaction that would affect investor assessment of the company's growth trajectory and capital allocation. The press release (EX-99.1) confirms this is the lead announcement: \"Signed a definitive agreement to acquire Cylinder Health, Inc., expanding into gastrointestinal care.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:41:21.456975+00:00","company_name":"Hinge Health, Inc.","ticker":"HNGE","filing_date":"2026-08-04"}]}